Zobrazeno 1 - 10
of 973
pro vyhledávání: '"P. Pozo- Rosich"'
Autor:
A. González Martínez, E. Hierro Roselló, J. Madera, V. García, Y. González-Osorio, E. Caronna, G. Gárate, L. Asskour, I. Fernández Lázaro, D. García-Azorín, S. Santos Lasaosa, P. Pozo- Rosich, Á. Guerrero-Peral, V. González-Quintanilla, J. Pascual, A. Mínguez-Olaondo, A. Gago-Veiga
Publikováno v:
Neurology Perspectives, Vol 4, Iss , Pp 6-7 (2024)
Externí odkaz:
https://doaj.org/article/868b411a460b453fba451e7a023b179b
Autor:
Richard B. Lipton, Stephanie J. Nahas, Patricia Pozo-Rosich, Tanya Bilchik, Peter McAllister, Michelle Finnegan, Yingyi Liu, Natty Chalermpalanupap, Brett Dabruzzo, David W. Dodick
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Atogepant is an oral calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of migraine in adults. These analyses evaluated the proportions of clinical trial participants who experienced sustai
Externí odkaz:
https://doaj.org/article/476947c9c4ae44f1950aaf9a3c55fac3
Autor:
Alicia Alpuente, Victor J. Gallardo, Laila Asskour, Edoardo Caronna, Marta Torres-Ferrus, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology, but
Externí odkaz:
https://doaj.org/article/b9c8613f71db4ae7bd153bd7c9d4fcf7
Autor:
Patricia Pozo-Rosich, Mafalda Carmo, Alejandro Muñiz, Beatriz Armada, Carlota Moya-Alarcón, Julio Pascual
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Migraine is a leading cause of disability, estimated to affect one-in-ten people in Spain. This study aimed to describe the management of migraine in Spain and identify improvement areas. Methods Non-interventional, retrospective,
Externí odkaz:
https://doaj.org/article/2e28f88ad3634c719c17152fda26f4b1
Autor:
Patricia Pozo-Rosich, José Luis Poveda, Carlos Crespo, María Martínez, José Manuel Rodríguez, Pablo Irimia
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treat
Externí odkaz:
https://doaj.org/article/9e56e67c0aaa4c0bba3fd0661e36d71c
Autor:
Carlos Lazaro-Hernandez, Edoardo Caronna, Joana Rosell-Mirmi, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is restricted in many countries due to
Externí odkaz:
https://doaj.org/article/002b1a3b20cf45ffa8bdf62cd3d41a3c
Autor:
Patricia Pozo-Rosich, Messoud Ashina, Stewart J. Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 339-353 (2024)
Abstract Introduction In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across th
Externí odkaz:
https://doaj.org/article/db3613d3bbe843fc9dda99c7098d8dd2
Autor:
María Pilar Navarro-Pérez, Vicente González-Quintanilla, Albert Muñoz-Vendrell, Elisabet Madrigal, Alicia Alpuente, Germán Latorre, Francis Molina, María José Monzón, Vicente Medrano, David García-Azorín, Carmen González-Oria, Ana Gago-Veiga, Fernando Velasco, Isabel Beltrán, Noemí Morollón, Javier Viguera, Javier Casas-Limón, Jaime Rodríguez-Vico, Elisa Cuadrado, Pablo Irimia, Fernando Iglesias, Ángel Luis Guerrero-Peral, Robert Belvís, Patricia Pozo-Rosich, Julio Pascual, Sonia Santos-Lasaosa
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundReal-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profil
Externí odkaz:
https://doaj.org/article/0a59df749dd94d6c9e8640bd61de3428
Autor:
Guanglu Li, Shaojie Duan, International Headache Genetics Consortium (IHGC), Tao Zheng, Tiantian Zhu, Baoquan Qu, Lei Liu, Zunjing Liu, Verneri Anttila, Ville Artto, Andrea C Belin, Anna Bjornsdottir, Gyda Bjornsdottir, Dorret I Boomsma, Sigrid Børte, Mona A Chalmer, Daniel I Chasman, Bru Cormand, Ester Cuenca-Leon, George Davey-Smith, Irene de Boer, Martin Dichgans, Tonu Esko, Tobias Freilinger, Padhraig Gormley, Lyn R Griffiths, Eija Hämäläinen, Thomas F Hansen, Aster VE Harder, Heidi Hautakangas, Marjo Hiekkala, Maria G Hrafnsdottir, M. Arfan Ikram, Marjo-Riitta Järvelin, Risto Kajanne, Mikko Kallela, Jaakko Kaprio, Mari Kaunisto, Lisette JA Kogelman, Espen S Kristoffersen, Christian Kubisch, Mitja Kurki, Tobias Kurth, Lenore Launer, Terho Lehtimäki, Davor Lessel, Lannie Ligthart, Sigurdur H Magnusson, Rainer Malik, Bertram Müller-Myhsok, Carrie Northover, Dale R Nyholt, Jes Olesen, Aarno Palotie, Priit Palta, Linda M Pedersen, Nancy Pedersen, Matti Pirinen, Danielle Posthuma, Patricia Pozo-Rosich, Alice Pressman, Olli Raitakari, Caroline Ran, Gudrun R Sigurdardottir, Hreinn Stefansson, Kari Stefansson, Olafur A Sveinsson, Gisela M Terwindt, Thorgeir E Thorgeirsson, Arn MJM vanden Maagdenberg, Cornelia van Duijn, Maija Wessman, Bendik S Winsvold, John-Anker Zwart.
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundMigraine has an increased prevalence in several immune disorders, but genetic cause-effect relationships remain unclear. Mendelian randomization (MR) was used in this study to explore whether immune diseases are causally associated with mig
Externí odkaz:
https://doaj.org/article/a30f6c7b567e43149a0c5afd66373445
Autor:
Shengyuan Yu, Jiying Zhou, Guogang Luo, Zheman Xiao, Anders Ettrup, Gary Jansson, Ioana Florea, Kristina Ranc, Patricia Pozo-Rosich
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background For some people with migraine, despite taking greater amounts of acute headache medication (AHM), they develop an increase in monthly headache days. This cycle of increasing headache days, and in turn AHM use, can lead to a second
Externí odkaz:
https://doaj.org/article/e9e9d427ec264f7f8d5d53e8c92478ce